대한약학회:학술대회논문집 (Proceedings of the PSK Conference)
- 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
- /
- Pages.424.1-424.1
- /
- 2002
Pharmacokinetics of DA-3021 (mono-PEGylated recombinant human interferon ($\alpha$ -2a) after Subcutaneous Administrations to Experimental Animals
- Jo, Yeong-Woo (Research Laboratories, Dong-A Pharm. Col, Ltd.) ;
- Kim, Won-Geun (College of Pharmacy. Sungkyunkwan University) ;
- Choi, Yun-Kyu (College of Pharmacy. Seoul National University) ;
- Jeon, Hyun-Kyu (College of Pharmacy. Seoul National University) ;
- Kim, Dong-Hwan (College of Pharmacy. Seoul National University) ;
- Park, Beom-Soo (College of Pharmacy. Seoul National University) ;
- Lee, Sung-Hee (College of Pharmacy. Seoul National University) ;
- Kim, Won-Bae (College of Pharmacy. Seoul National University) ;
- Youn, Yu-Seok (College of Pharmacy. Seoul National University)
- 발행 : 2002.10.01
초록
Interferon has therapeutic potential for a wide range of infectious and proliferative disorders such as chronic hepatitis C and malignant melanoma. However. it has some therapeutic problems as other protein therapeutics do. A variety of approaches have been developed to circumvent these problems. Among them. the attachment of a polyethylene glycol (PEG) moiety 10 interferon is considered as one of the most promising solutions for its ability of extending the plasma residence time. (omitted)
키워드